Patients know instantly when the FDA and/or EMA approved a new orphan drug.
Patients know exactly where and when novel treatments are developed, approved and made available.
Patients don’t think in terms of geographies i.e., US, Europe, Asia, Australasia, Latin America or Africa.
Patients don't care about the company's business plans and where a company decided to introduce its product first.
Patients regardless of where they live, want to be treated when needed.
Patients don't care whether the product is a branded orphan drug or a bio-equivalent generic biologic as long as they can be treated with an appropriate, safe, efficacious and approved product for which they might have been waiting for, for years and sometimes even decades.